F Pages, J Taieb, P Laurent-Puig, and J Galon
The consensus Immunoscore in phase 3 clinical trials; potential impact on patient management decisions
OncoImmunology
https://doi.org/10.1080/2162402X.2020.1812221
https://doi.org/10.1080/2162402X.2020.1812221
A Lanzi,F Pages, C Lagorce-Pages, and J Galon
The consensus immunoscore: toward a new classification of colorectal cancer
OncoImmunology
https://doi.org/10.1080/2162402X.2020.1789032
https://www.tandfonline.com/doi/full/10.1080/2162402X.2020.1789032
A Lanzi,F.A Sinicrope, A.B Benson, and J Galon
The consensus Immunoscore in phase 3 clinical trial (N0147) and impact on patient management decisions
OncoImmunology
https://doi.org/10.1080/2162402X.2020.1796003
https://doi.org/10.1080/2162402X.2020.1796003
El Sissy C, Kirilovsky A, Van den Eynde M et al.
A Diagnostic Biopsy-Adapted Immunoscore Predicts Response to Neoadjuvant Treatment and Selects Patients with Rectal Cancer Eligible for a Watch-and-Wait Strategy
Clin Cancer Res
10.1158/1078-0432.CCR-20-0337
https://clincancerres.aacrjournals.org/content/early/2020/08/21/1078-0432.CCR-20-0337
Mlecnik B Bifulco C, Bindea G, et al.
Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer
J Clin Oncol.
DOI: 10.1200/JCO.19.03205
https://ascopubs.org/doi/abs/10.1200/JCO.19.03205
Bruni D, K Angell H and Galon J
The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy
Nature Reviews Cancer
doi: 10.1038/s41568-020-0285-7
https://www.nature.com/articles/s41568-020-0285-7
O’Connor JM, Esteso F & Chacón M
Official French SARS-CoV-2 guidelines for cancer patients, a triage solution with precision medicine
Future Medicine
Colorectal Cancer | Ahead of Print
https://www.futuremedicine.com/doi/10.2217/crc-2020-0018
Blair H
Immunoscore®: A Diagnostic Assay for Clinical Management of Colon Cancer
Molecular Diagnosis & Therapy volume
24, pages365–370(2020)
https://link.springer.com/article/10.1007/s40291-020-00459-6
Marliot F, Chen X, Kirilovsky A et al.
Analytical validation of the Immunoscore and its associated prognostic value in patients with colon cancer
BMJ
http://dx.doi.org/10.1136/jitc-2019-000272
https://jitc.bmj.com/content/8/1/e000272
Sinicrope F, Shi Q, Hermitte F et al.
Contribution of Immunoscore and Molecular Features to Survival Prediction in Stage III Colon Cancer
JNCI Cancer Spectrum
Volume 4, Issue 3, June 2020, pkaa023
https://academic.oup.com/jncics/article/4/3/pkaa023/5812786
Pages F, Andre T, Taieb J et al.
Prognostic and Predictive Value of the Immunoscore in Stage III Colon Cancer Patients Treated With Oxaliplatin in the Prospective IDEA France PRODIGE-GERCOR Cohort Study
Annals of Oncology
PMID: 32294529
https://pubmed.ncbi.nlm.nih.gov/32294529/
Pages F, Andre T, Taieb J et al.
Validation of the Immunoscore prognostic value in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France cohort study (PRODIGE-GERCOR)
Journal of Clinical Oncology
Volume 37, Issue 15_suppl
https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.3513
Galon J & Bruni D
Tumor Immunology and Tumor Evolution: Intertwined Histories
Immunity
https://doi.org/10.1016/j.immuni.2019.12.018
https://www.cell.com/immunity/fulltext/S1074-7613(19)30537-0
Galon J & Bruni D
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies.
Nat Rev Drug Discov.
18(3):197-218
https://www.ncbi.nlm.nih.gov/pubmed/30610226
Mlecnik B, Bindea G, Angell HK et al.
Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability.
Immunity
44(3):698-711
https://www.ncbi.nlm.nih.gov/pubmed/26982367
Galon J, Costes A, Sanchez-Cabo F et al.
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome.
Science
313(5795):1960-4
https://www.ncbi.nlm.nih.gov/pubmed/17008531
Pagès F, Kirilovsky A, Mlecnik B et al.
In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer.
Journal of Clinical Oncology
27(35):5944-51
https://www.ncbi.nlm.nih.gov/pubmed/19858404
Mlecnik B, Tosolini M, Kirilovsky A et al.
Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction.
Journal of Clinical Oncology
29(6):610-8
https://www.ncbi.nlm.nih.gov/pubmed/21245428
Kirilovsky A, Marliot F, El Sissy C et al.
Rational bases for the use of the Immunoscore in routine clinical settings as a prognostic and predictive biomarker in cancer patients.
Int Immunol.
28(8):373-82
https://www.ncbi.nlm.nih.gov/pubmed/27121213
Pagès F, Mlecnik B, Marliot F et al.
International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study.
Lancet
391 (10135)
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)30789-X/fulltext
Sinicrope F, Shi Q, Hermitte F et al.
Association of immune markers and Immunoscore with survival of stage III colon carcinoma (CC) patients (pts) treated with adjuvant FOLFOX: NCCTG N0147 (Alliance).
J Clin Oncol.
35:15s (suppl; abstr 3579)
https://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.3579
Sinicrope F, Shi Q, Hermitte F et al.
Immunoscore to provide prognostic information in low- (T1-3N1) and high-risk (T4 or N2) subsets of stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147; Alliance).
J Clin Oncol.
36:4s (suppl; abstr 614)
https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.4_suppl.614
Angelova M, Mlecnik B, Vasaturo A et al.
Evolution of Metastases in Space and Time under Immune Selection.
Cell
10.1016/j.cell.2018.09.018
https://www.cell.com/cell/fulltext/S0092-8674(18)31230-3
Fridman WH, Pagès F, Sautès-Fridman C, Galon J.
The immune contexture in human tumours: impact on clinical outcome.
Nat Rev Cancer.
12(4):298-306
https://www.ncbi.nlm.nih.gov/pubmed/22419253
Galon J, Angell HK, Bedognetti D, Marincola FM
The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures.
Immunity
39(1):11-26
https://www.ncbi.nlm.nih.gov/pubmed/23890060
Bindea G, Mlecnik B, Tosolini M et al.
Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer.
Immunity
39(4):782-95
https://www.ncbi.nlm.nih.gov/pubmed/24138885
Berghoff AS, Fuchs E, Ricken G et al.
Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases.
Oncoimmunology
5(1):e1057388
https://www.ncbi.nlm.nih.gov/pubmed/26942067
Mlecnik B, Bindea G, Kirilovsky A et al.
The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis.
Sci Transl Med.
8(327):327ra26
https://www.ncbi.nlm.nih.gov/pubmed/26912905
Galon J, Mlecnik B, Marliot F et al.
Validation of the Immunoscore (IM) as a prognostic marker in stage I/II/III colon cancer: Results of a worldwide consortium-based analysis of 1,336 patients.
J Clin Oncol.
JCO.2016.34.15_suppl.3500
https://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.3500
Hermitte F
Biomarkers immune monitoring technology primer: Immunoscore® Colon.
Journal for ImmunoTherapy of Cancer
doi:10.1186/s40425-016-0161-x
https://jitc.biomedcentral.com/articles/10.1186/s40425-016-0161-x
Fridman WH, Zitvogel L, Sautès-Fridman C, Kroemer G
The immune contexture in cancer prognosis and treatment.
Nat Rev Clin Oncol.
14(12):717-734
https://www.ncbi.nlm.nih.gov/pubmed/28741618
Mlecnik B, Van den Eynde M, Bindea G et al.
Comprehensive Intrametastatic Immune Quantification and Major Impact of Immunoscore on Survival.
J Natl Cancer Inst.
1;110(1)
https://www.ncbi.nlm.nih.gov/pubmed/28922789
Angell HK, Bruni D, Barrett JC et al.
The Immunoscore: Colon Cancer and Beyond.
Clin Cancer Res.
doi: 10.1158/1078-0432
https://www.ncbi.nlm.nih.gov/pubmed/31413009
Zeitoun G, Sissy CE, Kirilovsky A et al.
The Immunoscore in the Clinical Practice of Patients with Colon and Rectal Cancers.
Chirurgia (Bucur).
114(2):152-161
https://www.ncbi.nlm.nih.gov/pubmed/31060646
Mascaux C, Angelova M, Vasaturo A et al.
Immune evasion before tumour invasion in early lung squamous carcinogenesis.
Nature
571(7766):570-575
https://www.ncbi.nlm.nih.gov/pubmed/31243362